KIT and acute myeloid leukemia: Tandutinib, can supress the autophosphorylation of FLT3, c-KIT and PDGF (platelet-derived growth factor) receptor tyrosine kinases, thereby inhibiting cellular proliferation and inducing apoptosis in AML [32].